Home » Posts tagged with » age-related macular degeneration
Novartis bags Beovu FDA approval for wet AMD

Novartis bags Beovu FDA approval for wet AMD

Beovu FDA approval for wet AMD : Swiss pharma giant Novartis has been given approval from the US Food and Drug Administration (FDA) for Beovu (brolucizumab) injection for wet age-related macular degeneration (AMD). Also called RTH258, Beovu is now the first FDA approved anti-VEGF which is said to deliver greater fluid resolution compared to aflibercept. […]

Graybug Vision initiates ALTISSIMO clinical trial for GB-102 in wet AMD

Graybug Vision has initiated the ALTISSIMO clinical trial, a phase 2b study, which will evaluate its pan-VEGF receptor inhibitor GB-102 in patients with wet age-related macular degeneration (wet AMD). Based in California, Graybug Vision is a clinical-stage pharma company engaged in developing drugs for ocular diseases like wet AMD, diabetic macular edema (DME), primary open […]

Continue reading …
Gemini Therapeutics appoints Jason Meyenburg as CEO

US precision medicine company Gemini Therapeutics, which is focused on developing treatments for age-related macular degeneration (AMD) and linked ocular disorders, has appointed Jason Meyenburg as its Chief Executive Officer (CEO). Jason Meyenburg will also join the Board of Directors of Gemini Therapeutics. Stephen Squinto – Gemini Therapeutics Board Director said: “We are thrilled to have […]

Continue reading …